Aignostics presenting new research and collaborations at AACR 2023
April 14, 2023
At this year's annual meeting of the American Association of Cancer Research ("AACR"), Aignostics will present the results of two reserach collaborations with Boehringer Ingelheim.
Where: Artificial Intelligence: From Pathomics to Radiomics / Section 33
When: April 18, 2023, 1:30 pm - 5:00 pm.
Respective abstracts and posters can be found here:
5423 - AI powered quantification of mitotic rate in H&E stained tissue detects significant differences between treatment groups of preclinical pancreas cancer xenografts
In addition, Aignostics will participate in an expert session with Discovery Life sciences on their joint efforts in building up mutliplex IF solutions for research and clinical trials.
Sharon Ruane, Ph.D. (Head of Scientific Programs at Aignostics) and Dirk Zielinski, Ph.D. (Head Assay Developmentat Discovery Life Sciences) will be the representing Aignostics and DLS.
Where: AACR Booth # 243
When: Tuesday, 4/18/2023, 1pm ET
Aignostics specializes in AI-powered pathology, uniquely combining proprietary technology, its pathologist network, and comprehensive access to key data modalities to build bespoke AI models for its global pharma and biotech client base. These AI models can deliver valuable insights into disease biology from tissue samples, such as novel biomarkers and drug response characteristics.
Aignostics formally started in 2018 in the Digital Health Accelerator program of the Berlin Institute of Health (BIH), based on joint research by Charité – Universitätsmedizin Berlin, one of Europe’s largest university hospitals, led by Prof. Frederick Klauschen, and TU Berlin, led by Prof. Klaus-Robert Müller. In early 2020, Aignostics was spun-out of Charité. To date, Aignostics has raised close to €20million in funding from leading VC investors and has offices in Berlin, Germany, and Boston, U.S.
Viktor Matyas, CEO
MC Services AG
Kaja Skorka, Dr. Regina Lutz
Phone: +49 89-210 2280